BRIAN P BEESLEY
- Type
- Physician · Allopathic & Osteopathic Physicians / General Practice
- Where
- REXBURG, ID
- NPI
- 1205129897
- Received
- $21,006 in 21 records, 2019 to 2025 ($319 general, $20,687 research)
- As principal investigator
- $232,507 of research payments to others in 17 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 2 | $46 |
| 2024 | Research payment | 2 | $19,957 |
| 2023 | General payment | 2 | $40 |
| 2023 | Research payment | 1 | $730 |
| 2022 | General payment | 3 | $58 |
| 2021 | General payment | 3 | $44 |
| 2020 | General payment | 4 | $69 |
| 2019 | General payment | 4 | $59 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 3 | $20,687 | 2023–2024 |
| Gilead Sciences, Inc. | 9 | $152 | 2019–2025 |
| iRhythm Technologies, Inc. | 2 | $51 | 2022–2023 |
| Abbott Laboratories | 3 | $48 | 2021–2023 |
| Amarin Pharma, Inc. | 2 | $39 | 2020–2021 |
| Tandem Diabetes Care, Inc. | 1 | $16 | 2022 |
| E.R. Squibb & Sons, L.L.C. | 1 | $11 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 3 | $20,687 |
| Food and Beverage | 18 | $319 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-07-15 | Gilead Sciences, Inc. | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-11 | Gilead Sciences, Inc. | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2024-09-24 | Eli Lilly and Company | $19,387 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED | 2024 | |
| 2024-09-24 | Eli Lilly and Company | $570 | Research payment | Cash or cash equivalent | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 | |
| 2023-03-28 | Eli Lilly and Company | $730 | Research payment | In-kind items and services | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 | |
| 2023-03-15 | iRhythm Technologies, Inc. | $21 | Food and Beverage | In-kind items and services | ZIO XT Patch Device, Cardiology/Vascular Diseases | 2023 | |
| 2023-02-16 | Abbott Laboratories | $19 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2023 | |
| 2022-08-24 | iRhythm Technologies, Inc. | $30 | Food and Beverage | In-kind items and services | ZIO XT Patch Device, Cardiology/Vascular Diseases | 2022 | |
| 2022-08-24 | Abbott Laboratories | $11 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2022 | |
| 2022-05-04 | Tandem Diabetes Care, Inc. | $16 | Food and Beverage | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2022 | |
| 2021-10-01 | Abbott Laboratories | $17 | Food and Beverage | In-kind items and services | FreeStyle Libre Device, Diabetes Care | 2021 | |
| 2021-06-13 | Gilead Sciences, Inc. | $11 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-01-07 | Amarin Pharma, Inc. | $15 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2020-12-09 | Gilead Sciences, Inc. | $11 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-07-27 | Amarin Pharma, Inc. | $23 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-07-15 | Gilead Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-03-07 | Gilead Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | 2020 | ||
| 2019-12-06 | Gilead Sciences, Inc. | $21 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-08-06 | Gilead Sciences, Inc. | $13 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-05-21 | E.R. Squibb & Sons, L.L.C. | $11 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2019 | |
| 2019-02-12 | Gilead Sciences, Inc. | $13 | Food and Beverage | In-kind items and services | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-06-17 | Eli Lilly and Company | ELITE CLINICAL TRIALS LLLP | $29,471 | A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PAR | 2025 |
| 2025-04-30 | Eli Lilly and Company | ELITE CLINICAL TRIALS LLLP | $165 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-04-20 | Eli Lilly Export S.A. Puerto Rico Branch | ELITE CLINICAL TRIALS LLLP | $4,493 | A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PAR | 2025 |
| 2025-01-31 | Eli Lilly and Company | ELITE CLINICAL TRIALS INC DBA ELLIOT MOON | $859 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-01-31 | Eli Lilly and Company | ELITE CLINICAL TRIALS LLLP | $924 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED | 2025 |
| 2025-01-21 | Eli Lilly and Company | ELITE CLINICAL TRIALS LLLP | $30,033 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED | 2025 |
| 2025-01-21 | Eli Lilly and Company | ELITE CLINICAL TRIALS LLLP | $25,687 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2024-02-13 | Eli Lilly and Company | ELITE CLINICAL TRIALS LLLP | $54,232 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED | 2024 |
| 2024-01-31 | Eli Lilly and Company | ELITE CLINICAL TRIALS LLLP | $1,338 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED | 2024 |
| 2024-01-30 | Eli Lilly and Company | ELITE CLINICAL TRIALS LLLP | $54,132 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-01-16 | Eli Lilly and Company | ELITE CLINICAL TRIALS LLLP | $375 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-01-12 | Eli Lilly and Company | ELITE CLINICAL TRIALS INC DBA ELLIOT MOON | $1,478 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2023-12-29 | Eli Lilly and Company | ELITE CLINICAL TRIALS INC DBA ELLIOT MOON | $535 | A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WI | 2023 |
| 2023-12-11 | Eli Lilly and Company | ELITE CLINICAL TRIALS LLLP | $289 | A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WI | 2023 |
| 2023-06-20 | Eli Lilly and Company | ELITE CLINICAL TRIALS LLLP | $26,703 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 |
| 2023-03-23 | Eli Lilly and Company | ELITE CLINICAL TRIALS LLLP | $712 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 |
| 2023-03-10 | Eli Lilly and Company | ELITE CLINICAL TRIALS INC DBA ELLIOT MOON | $1,077 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rexburg, ID, county Madison County, ID, state Idaho; placed by its city name.
| Measure | Place (city or town) Rexburg, ID | County Madison County, ID | State Idaho |
|---|---|---|---|
| Population B01003 | 40,543 | 54,618 | 1,934,262 |
| Population, 2020 census P1 | 39,409 | 52,913 | 1,839,106 |
| Median age B01002 | 21.0 | 21.4 | 37.3 |
| Under 18 B01001 | 15.4% | 20.2% | 24.1% |
| 65 and over B01001 | 2.9% | 5.4% | 17.0% |
| Households B11001 | 9,410 | 13,326 | 713,005 |
| Foreign born B05002 | 6.5% | 5.2% | 5.9% |
| Median household income B19013 | $50,617 | $60,160 | $77,800 |
| Median family income B19113 | $54,056 | $65,935 | $92,668 |
| Per capita income B19301 | $21,417 | $23,958 | $38,952 |
| Poverty rate B17001 | 32.5% | 24.5% | 10.6% |
| Unemployment rate B23025 | 8.8% | 8.3% | 3.7% |
| Civilian labor force B23025 | 24,379 | 30,852 | 954,904 |
| Mean commute (minutes) B08013 | 15.2 | 16.4 | 21.6 |
| Bachelor's degree or higher B15003 | 42.0% | 41.8% | 31.8% |
| Housing units B25001 | 10,834 | 15,145 | 795,014 |
| Owner-occupied B25003 | 23.0% | 40.2% | 72.1% |
| Renters B25003 | 77.0% | 59.8% | 27.9% |
| Median home value B25077 | $395,100 | $414,800 | $418,600 |
| Median gross rent B25064 | $1,004 | $1,014 | $1,238 |
| White, not Hispanic B03002 | 81.2% | 83.5% | 78.6% |
| Black B03002 | 1.2% | 1.0% | 0.7% |
| Hispanic or Latino B03002 | 11.2% | 9.8% | 13.6% |
| Asian B03002 | 1.7% | 1.5% | 1.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.7% |
Economy now FRED unemployment 3.6% in Sep 2026 (3.6% a year earlier); per capita personal income $64,200 in 2025, up 29% in five years (+3.8% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rexburg, ID.
Comments